These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16513858)

  • 1. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.
    Spencer TJ; Biederman J; Ciccone PE; Madras BK; Dougherty DD; Bonab AA; Livni E; Parasrampuria DA; Fischman AJ
    Am J Psychiatry; 2006 Mar; 163(3):387-95. PubMed ID: 16513858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the central pharmacokinetics of spheroidal oral drug absorption system (SODAS) dexmethylphenidate: a positron emission tomography study of dopamine transporter receptor occupancy measured with C-11 altropane.
    Spencer TJ; Bonab AA; Dougherty DD; Mirto T; Martin J; Clarke A; Fischman AJ
    J Clin Psychiatry; 2012 Mar; 73(3):346-52. PubMed ID: 22154896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults.
    Spencer TJ; Bonab AA; Dougherty DD; Martin J; McDonnell T; Fischman AJ
    Int J Mol Med; 2010 Feb; 25(2):261-5. PubMed ID: 20043136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate.
    Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Logan J; Ding YS; Hitzemann R; Pappas N
    Am J Psychiatry; 1998 Oct; 155(10):1325-31. PubMed ID: 9766762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo activity of modafinil on dopamine transporter measured with positron emission tomography and [¹⁸F]FE-PE2I.
    Kim W; Tateno A; Arakawa R; Sakayori T; Ikeda Y; Suzuki H; Okubo Y
    Int J Neuropsychopharmacol; 2014 May; 17(5):697-703. PubMed ID: 24451483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of methylphenidate blocks the effect of cocaine on uptake at the Drosophila dopamine transporter.
    Berglund EC; Makos MA; Keighron JD; Phan N; Heien ML; Ewing AG
    ACS Chem Neurosci; 2013 Apr; 4(4):566-74. PubMed ID: 23402315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain.
    Volkow ND; Wang G; Fowler JS; Logan J; Gerasimov M; Maynard L; Ding Y; Gatley SJ; Gifford A; Franceschi D
    J Neurosci; 2001 Jan; 21(2):RC121. PubMed ID: 11160455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: dopamine transporter occupancy as measured by PET.
    Appel L; Bergström M; Buus Lassen J; Långström B
    Eur Neuropsychopharmacol; 2014 Feb; 24(2):251-61. PubMed ID: 24239329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between psychostimulant-induced "high" and dopamine transporter occupancy.
    Volkow ND; Wang GJ; Fowler JS; Gatley SJ; Ding YS; Logan J; Dewey SL; Hitzemann R; Lieberman J
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10388-92. PubMed ID: 8816810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans.
    Gatley SJ; Volkow ND; Gifford AN; Fowler JS; Dewey SL; Ding YS; Logan J
    Psychopharmacology (Berl); 1999 Sep; 146(1):93-100. PubMed ID: 10485970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications.
    Volkow ND; Wang GJ; Fowler JS; Logan J; Franceschi D; Maynard L; Ding YS; Gatley SJ; Gifford A; Zhu W; Swanson JM
    Synapse; 2002 Mar; 43(3):181-7. PubMed ID: 11793423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).
    Swanson JM; Wigal SB; Wigal T; Sonuga-Barke E; Greenhill LL; Biederman J; Kollins S; Nguyen AS; DeCory HH; Hirshe Dirksen SJ; Hatch SJ;
    Pediatrics; 2004 Mar; 113(3 Pt 1):e206-16. PubMed ID: 14993578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic-Pharmacodynamic Modeling of Brain Dopamine Levels Based on Dopamine Transporter Occupancy after Administration of Methylphenidate in Rats.
    Shimizu R; Horiguchi N; Yano K; Sakuramoto M; Kanegawa N; Shinohara S; Ohnishi S
    J Pharmacol Exp Ther; 2019 Apr; 369(1):78-87. PubMed ID: 30674560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.
    Volkow ND; Swanson JM
    Am J Psychiatry; 2003 Nov; 160(11):1909-18. PubMed ID: 14594733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.
    Modi NB; Wang B; Noveck RJ; Gupta SK
    J Clin Pharmacol; 2000 Oct; 40(10):1141-9. PubMed ID: 11028253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine.
    Gatley SJ; Volkow ND; Gifford AN; Ding YS; Logan J; Wang GJ
    Biochem Pharmacol; 1997 Jan; 53(1):43-52. PubMed ID: 8960062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.